Literature DB >> 29602408

An Update on Hypertension in Children With Type 1 Diabetes.

Mallory L Downie1, Emma H Ulrich1, Damien G Noone2.   

Abstract

The prevalence of hypertension in children with type 1 diabetes is reported to be between 6% and 16%. This potentially modifiable cardiovascular risk factor may go undiagnosed and undertreated, particularly in children with type 1 diabetes. Recent updated Canadian clinical practice guidelines recommend blood pressure screening every 2 years in children with type 1 diabetes as well as routine use of ambulatory blood pressure monitoring. Risk factors for hypertension in type 1 diabetes include poor glycemic control, overweight and obesity and genetic predisposition for hypertension. In terms of pathophysiology, sustained hyperglycemia, angiotensin I and II and inflammatory cytokines have been implicated. Endothelial and vascular dysfunction, with impaired endothelial-dependent vasodilation and increased carotid artery intima-media thickness, are evident in preclinical and clinical studies of children and not just in adults with type 1 diabetes. Early targeted therapy is critical to the control of hypertension and the development of related morbidity. As with hypertension in adults with type 1 diabetes, lifestyle modifications remain first-line therapy, including diet and glycemic control. Initial antihypertensive therapy should be an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker because of their associated effects of reducing microalbuminuria and improving renovascular outcomes. Pediatric hypertension in type 1 diabetes is an area of evolving study and opinion; identification and appropriate treatment is critical for the prevention of micro- and macrovascular complications in adulthood.
Copyright © 2018 Diabetes Canada. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adolescents; angiotensin receptor blocker; angiotensin-converting enzyme inhibitor; blood pressure; bloqueur du récepteur à l’angiotensine; dysfonctions endothéliales; endothelial dysfunction; inhibiteur de l’enzyme de conversion de l’angiotensine; pression artérielle

Mesh:

Year:  2018        PMID: 29602408     DOI: 10.1016/j.jcjd.2018.02.008

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN: 1499-2671            Impact factor:   4.190


  6 in total

Review 1.  Ambulatory Blood Pressure Monitoring in Pediatrics.

Authors:  Sonali S Patel; Stephen R Daniels
Journal:  Curr Hypertens Rep       Date:  2019-07-26       Impact factor: 5.369

2.  Anthropometric Measurements and Laboratory Investigations in Children and Youth With Type 1 Diabetes Before and During the COVID-19 Pandemic.

Authors:  Carolina Silva; Qian Zhang; Jeffrey N Bone; Shazhan Amed
Journal:  Can J Diabetes       Date:  2022-04-14       Impact factor: 2.774

3.  Decreased KLHL3 expression is involved in the activation of WNK-OSR1/SPAK-NCC cascade in type 1 diabetic mice.

Authors:  Qin Guo; Ya Zhang; Geng-Ru Jiang; Chong Zhang
Journal:  Pflugers Arch       Date:  2021-01-11       Impact factor: 3.657

4.  Technological Ecological Momentary Assessment Tools to Study Type 1 Diabetes in Youth: Viewpoint of Methodologies.

Authors:  Mary Katherine Ray; Alana McMichael; Maria Rivera-Santana; Jacob Noel; Tamara Hershey
Journal:  JMIR Diabetes       Date:  2021-06-03

5.  Children with type 1 diabetes have elevated high-sensitivity C-reactive protein compared with a control group.

Authors:  Pilar Pérez-Segura; Olaya de Dios; Leticia Herrero; Claudia Vales-Villamarín; Isabel Aragón-Gómez; Teresa Gavela-Pérez; Carmen Garcés; Leandro Soriano-Guillén
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07

6.  Analysis of the diet quality and dietary habits of children and adolescents with type 1 diabetes.

Authors:  Karolina Dłużniak-Gołaska; Mariusz Panczyk; Dorota Szostak-Węgierek; Agnieszka Szypowska; Beata Sińska
Journal:  Diabetes Metab Syndr Obes       Date:  2019-01-17       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.